CSV November 24, 2022 through November 24, 2024 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ABIRATERONE	PERFORMANC	*Revision*	Online	26-Jun-2020	1-Jul-2020	*NA*	*NA*	In *Analysis*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ACETATE TABLETS	E TESTS/ *Dissolution <711>/Test 3*	*Bulletin (Official November 19, 2019)*						Change r_U = peak response of abiratrone acetate from the *Sample solution* r_S = peak response of abiratrone acetate from the *Standard solution* to: r_U = peak response of abiraterone acetate from the *Sample solution* r_S = peak response of abiraterone acetate from the *Standard solution*
ATROPINE SULFATE OPHTHALMIC OINTMENT	ASSAY/ *Procedure*	*USP43–NF38*	431	26-Jun-2020	1-Jul-2020	*NA*	*NA*	In *Analysis*: Change atropine sulfate monohydrate, 694.83 to: atropine sulfate

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								monohydrate, 694.84
ISOSORBIDE MONONITRATE EXTENDED-RELEASE TABLETS	IMPURITIES/*Organic Impurities, Procedure 1/ Chromatographic system*	*Revision Bulletin (Official October 01, 2019)*	Online	26-Jun-2020	1-Jul-2020	*NA*	*NA*	In *Detection solution*: Change Dissolve 1.25 g of potassium permanganate and 10.0 g of sodium hydroxide in 500 mL of water (prepared fresh for each plate), and heat at 105° for 5 min. to: Dissolve 1.25 g of potassium permanganate and 10.0 g of sodium hydroxide in 500 mL of water (prepared fresh for each plate).
ATROPINE SULFATE	CHEMICAL INFORMATION	*USP43–NF38*	428	26-Jun-2020	1-Jul-2020	*NA*	*NA*	Change 694.83 to: 694.84

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
NOREPINEPHRINE BITARTRATE	CHEMICAL INFORMATION	*USP43–NF38*	3197	26-Jun-2020	1-Jul-2020	*NA*	*NA*	Change $C_8H_{11}NO_2 \cdot C_4H_6O_6$ to: $C_8H_{11}NO_3 \cdot C_4H_6O_6$
AMLODIPINE AND ATORVASTATIN TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*Revision Bulletin (Official November 27, 2019)*	Online	26-Jun-2020	1-Jul-2020	*NA*	*NA*	In USP Atorvastatin Related Compound B RS: Change (3*S*,5*R*)-7-[3-(Phenylcarbamoyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1*H*-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid calcium salt. to: Calcium (3*S*,5*R*)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1*H*-pyrrol-1-yl]-3,5-dihydroxyhepta

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								noate (1:2); also known as (3*S*,5*R*)-7-[3-(Phenylcarbamoyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1*H*-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid calcium salt.
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE ORAL SOLUTION	*Assay*	*USP43–NF38*	1438	26-Jun-2020	1-Jul-2020	*NA*	*NA*	In *Procedure*: Change (694.83/676.83)(25)$C_A(r_U/r_S)$ in which 694.83 and 676.83 are the molecular weights of atropine sulfate monohydrate and anhydrous atropine sulfate, respectively; to: (694.84/676.82)(25)$C_A(r_U/r_S)$ in which 694.84 and 676.82 are the molecular

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								weights of atropine sulfate monohydrate and anhydrous atropine sulfate, respectively;
ATROPINE SULFATE INJECTION	ASSAY/ *Procedure*	*USP43–NF38*	430	26-Jun-2020	1-Jul-2020	*NA*	*NA*	In *Analysis*: Change atropine sulfate monohydrate, 694.85 to: atropine sulfate monohydrate, 694.84 AND Change anhydrous atropine sulfate, 676.83 to: anhydrous atropine sulfate, 676.82
PROPYLENE CARBONATE	ASSAY/ *Procedure/Titrimetric system*	*USP43–NF38*	5986	26-Jun-2020	1-Jul-2020	*NA*	*NA*	In *Mode*: Change Direct titration to: Residual titration
METOPROLOL	*USP Reference*	*USP43–NF38*	2917	29-May-2020	1-Jun-2020	*NA*	*NA*	In USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SUCCINATE	*standards <11>*							Metoprolol Related Compound C RS: Change (±)4-[2-Hydroxy-3-(1-methylethyl)aminopropoxy]benzaldehyde. $C_{13}H_{19}NO_3$ 237.29 to: 4-[2-Hydroxy-3-(isopropylamino)propoxy]benzaldehyde hydrochloride. $C_{13}H_{19}NO_3 \cdot HCl$ 273.76 AND In USP Metoprolol Related Compound D RS: Change (±) *N*,*N*-Bis[2-hydroxy-3-[4-(2-methoxyethyl)phenoxy]propyl](1-methylethyl)amine.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FILGRASTIM	ASSAY/*Potency*	*USP43–NF38*	Online	29-May-2020	1-Jun-2020	*NA*	*NA*	$C_{27}H_{41}NO_6$ 475.62 to: *N*,*N* -Bis{2-hydroxy-3-[4-(2-methoxyethyl)phenoxy]propyl}isopropylamine hydrochloride; also known as (±) *N*,*N* -Bis[2-hydroxy-3-[4-(2-methoxyethyl)phenoxy]propyl](1-methylethyl)amine hydrochloride. $C_{27}H_{41}NO_6$ · HCl 512.08 In *Standard solution*: Change 0.5 ng/mL of in *Medium B*. to: 0.5 ng/mL of USP Filgrastim RS in *Medium B*. AND

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ROPIVACAINE HYDROCHLORIDE INJECTION	*USP Reference standards <11>*	*USP43–NF38*	3945	29-May-2020	1-Jun-2020	*NA*	*NA*	In *Positive control solution*: Change 10 ng/mL of in *Medium B* to: 10 ng/mL of USP Filgrastim RS in *Medium B* In USP Ropivacaine Related Compound A RS: Change 2,6-Dimethylaniline hydrochloride. $C_8H_{12}ClN$ 157.64 [CAS-21436-98-6]. to: 2,6-Dimethylaniline hydrochloride. $C_8H_{11}N \cdot HCl$ 157.64 AND In USP Ropivacaine Related

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Compound B RS: Change (*R*)-Ropivacaine hydrochloride monohydrate; (*R*)-(+)-1-propylpiperidine-2-carboxylic acid (2,6-dimethylphenyl)-amide hydrochloride monohydrate. $C_{17}H_{26}N_2O$ 328.89 to: (*R*)-Ropivacaine hydrochloride monohydrate; (*R*)-(+)-1-propylpiperidine-2-carboxylic acid (2,6-dimethylphenyl)-amide hydrochloride monohydrate; (*R*)-*N*-(2,6-Dimethylphenyl)-1-propylpiperidine-2-carb

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								oxamide hydrochloride monohydrate. $C_{17}H_{26}N_2O \cdot HCl \cdot H_2O$ 328.88
DOXYCYCLINE CAPSULES	PERFORMANCE TESTS	*USP43–NF38*	1519	29-May-2020	1-Jun-2020	*NA*	*NA*	In *Dissolution <711>*: Change *Test 2* to: *Test 2*: If the product complies with this test, the labeling indicates that it meets USP *Dissolution Test 2*.
DOLASETRON MESYLATE	ASSAY/ *Procedure*	*USP43–NF38*	1483	29-May-2020	1-Jun-2020	*NA*	*NA*	Change *Mobile phase*: Acetonitrile, water, and 1 M ammonium formate (450:440:110), adding 0.19 mL of triethylamine to the acetonitrile portion

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: *Solution A*: Add 0.19 mL of triethylamine to each 450 mL of acetonitrile. *Mobile phase*: *Solution A*, water, and 1 M ammonium formate (450:440:110)
INDOMETHACIN SUPPOSITORIES	ASSAY/ *Procedure*	*Revision Bulletin (Official December 01, 2019)*	Online	29-May-2020	1-Jun-2020	*NA*	*NA*	In *Chromatographic system/ Detector*: Change PDA (scan 200–600). to: PDA (scan 200–600 nm).
POWDERED BILBERRY EXTRACT	COMPOSITION	*USP43–NF38*	4813	29-May-2020	1-Jun-2020	*NA*	*NA*	In *Content of Anthocyanosides and Anthocyanidins/System suitability/Resolution*: Change petunidin-3-*O*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-arabinose to: petu nidin-3-*O* -arabinoside
FILGRASTIM	IM PUR ITIES/*Organic Impurities*	*USP43–NF38*	Online	29-May-2020	1-Jun-2020	*NA*	*NA*	In *Related Co mpoun ds*/*Standard solution*: Change 0.75 mg/mL of in water to: 0.75 mg/mL of USP Filgrastim RS in water AND In *Impurities with Charges Different from Filgra stim*/*Reference solution A*: Change 1 mg/mL of in water to: 1 mg/mL of USP Filgrastim RS in water

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								AND In *Impurities with Charges Different from Filgra stim/Reference solution B*: Change Dilute *Reference solution A* with water to obtain a concentration of 20 µg/mL of . to: Dilute *Reference solution A* with water to obtain a concentration of 20 µg/mL of USP Filgrastim RS. AND In *Impurities with Charges Different from Filgra stim/Reference solution C*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								3 mg/mL of in water to: 3 mg/mL of USP Filgrastim RS in water AND In *Impurities with Molecular Weight Different from That of Filgra stim/Reference solution A*: Change Dilute 25 µg of with 25 µL of *4X SDS sample buffer* and sufficient water to obtain 100 µL of a solution containing a 250-µg/mL preparation of in 1X SDS sample buffer. to: Dilute 25 µg of USP Filgrastim RS with 25 µL

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								of *4X SDS sample buffer* and sufficient water to obtain 100 µL of a solution containing a 250-µg/mL preparation of USP Filgrastim RS in 1X SDS sample buffer. AND In *Impurities with Molecular Weight Different from That of Filgra stim/Reference solution B*: Change Prepare both a reduced and a nonreduced *Reference solution B* by diluting *Reference solution A* (1:100) with the appropriate 1X

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								SDS sample buffer to obtain a 2.5-µg/mL preparation of . to: Prepare both a reduced and a nonreduced *Reference solution B* by diluting *Reference solution A* (1:100) with the appropriate 1X SDS sample buffer to obtain a 2.5-µg/mL preparation of USP Filgrastim RS. AND In *Impurities with Molecular Weight Different from That of Filgra stim*/*Reference solution C*: Change Dilute 75 µg of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								with 25 µL of *4X SDS sample buffer* and sufficient water to obtain 100 µL of a solution containing a 750-µg/mL preparation of in 1X SDS sample buffer. to: Dilute 75 µg of USP Filgrastim RS with 25 µL of *4X SDS sample buffer* and sufficient water to obtain 100 µL of a solution containing a 750-µg/mL preparation of USP Filgrastim RS in 1X SDS sample buffer. AND In *Limit of High Molecular Weight Proteins*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								/Resolution solution: Change Dissolve about 1 mg of in 0.33 mL of 0.25 M sucrose, to: Dissolve about 1 mg of USP Filgrastim RS in 0.33 mL of 0.25 M sucrose, AND In *Limit of High Molecular Weight Proteins /Standard solution*: Change 0.3 mg/mL of in water to: 0.3 mg/mL of USP Filgrastim RS in water
TETRACAINE HYDROCHLORIDE	IM PURITIES/*Organic Impurities*	*USP43–NF38*	4295	29-May-2020	1-Jun-2020	*NA*	*NA*	In *Table 2*: Change Tetracaine hydrochloride related

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								compound B 1.7 0.4 Tetracaine hydrochloride related compound C 2.1 0.4 to: Tetracaine related compound B 1.7 0.4 Tetracaine related compound C 2.1 0.4
PRAVASTATIN SODIUM	ADDITIONAL REQUIREMENTS	*USP43–NF38*	3645	29-May-2020	1-Jun-2020	*NA*	*NA*	In *USP Reference Standards <11>/USP Pravastatin Related Compound A RS*: Change 446.51 to: 446.52
FILGRASTIM	IDENTIFICATION/*C. Peptide Mapping*	*USP43–NF38*	Online	29-May-2020	1-Jun-2020	*NA*	*NA*	In *Standard solution*: Change Prepare a

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution containing 80 µg of and 200 µL of *Digestion solution* to: Prepare a solution containing 80 µg of USP Filgrastim RS and 200 µL of *Digestion solution* AND In *System suitability requirements*: Change Eight major peaks should be present in each chromatogram as illustrated in the reference chromatogram provided with . to: Eight major peaks should

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								be present in each chromatogram as illustrated in the reference chromatogram provided with USP Filgrastim RS.
ROPIVACAINE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS	*USP43–NF38*	3943	29-May-2020	1-Jun-2020	*NA*	*NA*	In *USP Reference Standards* <*11*>/USP Ropivacaine Related Compound A RS: Change 2,6-Dimethylaniline hydrochloride. $C_8H_{12}ClN$ 157.64 [CAS-21436-98-6]. to: 2,6-Dimethylaniline hydrochloride. $C_8H_{11}N \cdot HCl$ 157.64 AND In USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Ropivacaine Related Compound B RS: Change (*R*)-Ropivacaine hydrochloride monohydrate; (*R*)-(+)-1-propylpiperidine-2-carboxylic acid (2,6-dimethylphenyl)-amide hydrochloride monohydrate. $C_{17}H_{26}N_2O$ 328.89 to: (*R*)-Ropivacaine hydrochloride monohydrate; (*R*)-(+)-1-propylpiperidine-2-carboxylic acid (2,6-dimethylphenyl)-amide hydrochloride monohydrate; (*R*)-*N*-(2,6-Dimethylp

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								henyl)-1-propylpiperidine-2-carboxamide hydrochloride monohydrate. $C_{17}H_{26}N_2O \cdot HCl \cdot H_2O$ 328.88
DESCRIPTION AND SOLUBILITY	REAGENTS AND REFERENCE TABLES/REFERENCE TABLES	*USP43–NF38*	6275	29-May-2020	1-Nov-2020	*NA*	*NA*	Change *Incommunicable Acid Hydrochloride*: to: *Aminolevulinic Acid Hydrochloride*:
ANHYDROUS DIBASIC CALCIUM PHOSPHATE	ASSAY/ *Procedure*	*Harmonization (Official December 01, 2019)*	Online	29-May-2020	1-Jun-2020	*NA*	*NA*	In *Analysis*: Change *M* = actual molarity of the *Back-titrant* (mM/mL) to: *M* = actual molarity of the *Back-titrant* (mmol/mL) AND Change *F* = equivalency factor, 136.06

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								mg/mM to: *F* = equivalency factor, 136.06 mg/mmol
FILGRASTIM	ADDITIONAL REQUIREMENTS	*USP43–NF38*	Online	29-May-2020	1-Jun-2020	*NA*	*NA*	Change *USP Reference Standards <11>* to: *USP Reference Standards <11>* USP Filgrastim RS
TRANYLCYPROMINE SULFATE	CHEMICAL INFORMATION	*USP43–NF38*	Online	29-May-2020	1-Jun-2020	*NA*	*NA*	See https://www.usp nf.com/errata/tr anylcypromine-sulfate-image for correction.
RALTEGRAVIR TABLETS	DEFINITION	*USP43–NF38*	3834	24-Apr-2020	1-May-2020	*NA*	*NA*	Change ($C_{20}H_{20}FN_6O_5$) to: ($C_{20}H_{21}FN_6O_5$)
RALTEGRAVIR CHEWABLE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*USP43–NF38*	3835	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Analysis*: Change M_{r1} = molecular weight of raltegravir, 444.44 to: *M*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								r_1= molecular weight of raltegravir, 444.42
ALOSETRON HYDROCHLORIDE	IMPURITIES/*Organic Impurities*	*USP43–NF38*	141	24-Apr-2020	1-May-2020	*NA*	*NA*	In *System suitability/Suitability requirements/Resolution*: Change NLT 7 to: NLT 3
CALCIUM AND VITAMIN D WITH MINERALS TABLETS	STRENGTH	*USP43–NF38*	4845	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Calcium, Copper, Magnesium, Manganese, and Zinc, Method 2/Acceptance criteria*: Change NLT 90.0%–125.0% to: 90.0%–125.0%
DAPSONE TABLETS	IDENTIFICATION/*B.*	*USP43–NF38*	1241	24-Apr-2020	1-May-2020	*NA*	*NA*	Change *Ultraviolet Absorption* <197U>

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: *Spectroscopic Identification Tests* <197>, *Ultraviolet-Visible Spectroscopy*: 197U
WATER-SOLUBLE VITAMINS TABLETS	STRENGTH	*USP43–NF38*	5512	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Biotin, Method 3/Solid-phase extraction*: Change anion-xchange to: anion-exchange AND In the Calculate statement in *Niacin or Niacinamide, Pyridoxine Hydrochloride, Riboflavin, and Thiamine, Method 1/Analysis*: Delete , calcium pantothenate (C

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$_{18}H_{32}CaN_2O$ $_{10}$), and folic acid ($C_{19}H_{19}N_7O_6$), AND In the Calculate statement in *Niacin or Niacinamide, Pyridoxine Hydrochloride, Riboflavin, and Thiamine, Method 3/Analysis*: Delete , calcium pantothenate ($C_{18}H_{32}CaN_2O$ $_{10}$), and folic acid ($C_{19}H_{19}N_7O_6$), AND In the Calculate statement in *Folic Acid, Method 3; Ascorbic Acid, Niacin or Niacinamide, Pyridoxine*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Hydrochloride, Calcium Pantothenate, Riboflavin, and Thiamine, Method 4/Analysis: Add ascorbic acid ($C_6H_8O_6$),
EPINEPHRINE	IMPURITIES/ *Enantiomeric Purity*	*USP43–NF38*	Online	24-Apr-2020	1-May-2020	*NA*	*NA*	This erratum applies to the USP-NF ONLINE platform only. In *System suitability solution*: Change 0.03 mg/mL of in *Mobile phase* to: 0.03 mg/mL of USP Racepinephrine Hydrochloride RS in *Mobile phase*
POLYOXYL 35 CASTOR OIL	IDENTIFICATION/*C. Identity by Fatty Acid Composition*	*USP43–NF38*	5956	24-Apr-2020	1-May-2020	*NA*	*NA*	In *System suitability/Suitability requirements/Relative standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								deviation: Change linoeate to: linoleate
MENADIONE	ASSAY/ *Procedure*	*USP43–NF38*	2780	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Endpoint detection*: Change Potentiometric to: Visual
IDENTIFICATION TESTS—GENERAL	CHEMICAL IDENTIFICATION TESTS	*USP43–NF38*	6587	24-Apr-2020	1-Aug-2020	*NA*	*NA*	In *Bicarbonate*/*B.*: Change (1:20) to: (1 in 20) AND In *Borate*/*A.*: Change (1:50): to: (1 in 50): AND In *Calcium*/*A.*: Change (1:20) to: (1 in 20) AND In

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Carbonate/*B.*: Change (1:20) to: (1 in 20) AND In *Chloride*/*B.*: Change (1:100), to: (1 in 100), AND In *Cobalt*/*A.*: Change (1:20) to: (1 in 20) AND Change (1:10) to: (1 in 10) AND In *Tartrate*/*A.*: Change (1:20). to: (1 in 20).
PROPOFOL	IM PURITIES/*Organic*	*USP43–NF38*	3739	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Table 3*: Delete Propofol related

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Impurities, Procedure 2							compound B[b] 0.8 1.0 0.05 AND Change Propofol related compound A[c] to: Propofol related compound A[b] AND Change [b] 2,6-Diisopropylbenzoquinone. [c] 3,3?-5,5?-Tetraisopropyldiphenol. to: [b] 3,3?-5,5?-Tetraisopropyldiphenol.
RALTEGRAVIR TABLETS	IMPURITIES/*Organic Impurities*	*USP43–NF38*	3834	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Analysis*: Change M_{r1} = molecular weight of raltegravir, 444.44 to: *M*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								r_1= molecular weight of raltegravir, 444.42
VITAMIN A TABLETS	ASSAY/ *Procedure 2*	*USP43–NF38*	4635	24-Apr-2020	1-May-2020	*NA*	*NA*	In the variable definition list in *Analysis*: Change *Sample solution 1* to: *Sample solution*
CARISOPRODOL	IMPURITIES/*Organic Impurities*	*USP43–NF38*	776	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Table 2*: Change Carisoprdol related compound A[a] to: Carisoprodol related compound A[a]
OIL- AND WATER-SOLUBLE VITAMINS TABLETS	STRENGTH	*USP43–NF38*	5419	24-Apr-2020	1-May-2020	*NA*	*NA*	In the variable definition for *F* in *Vitamin E, Method 2/Analysis*: Change 1/2 for products labeled to contain *all-rac* vitamin E

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								sources) to: 1/2 (for products labeled to contain *all-rac* vitamin E sources) AND In *Biotin, Method 2/Basal medium stock solution*: Change Dissolve the anhydrous dextrose and anhydrous Sodium acetate to: Dissolve the anhydrous dextrose and anhydrous sodium acetate AND In *Cyanocobalamin, Method 2/Basal medium stock solution*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change thedextros, to: the dextrose, AND In the Calculate statement in *Niacin or Niacinamide, Pyridoxine Hydrochloride, Riboflavin, and Thiamine, Method 1/Analysis*: Delete , calcium pantothenate ($C_{18}H_{32}CaN_2O_{10}$), and folic acid ($C_{19}H_{19}N_7O_6$), AND In the Calculate statement in *Niacin or Niacinamide, Pyridoxine Hydrochloride, Riboflavin, and Thiamine,*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Method 3/Analysis: Delete , calcium pantothenate ($C_{18}H_{32}CaN_2O_{10}$), and folic acid ($C_{19}H_{19}N_7O_6$), AND In the Calculate statement in *Folic Acid, Method 3; Ascorbic Acid, Niacin or Niacinamide, Pyridoxine Hydrochloride, Calcium Pantothenate, Riboflavin, and Thiamine, Method 4/Analysis*: Add ascorbic acid ($C_6H_8O_6$)
DIHYDROERGOTAMINE MESYLATE	*Assay*	*USP43–NF38*	1388	24-Apr-2020	1-May-2020	*NA*	*NA*	Change *Diluent 1*—Prepare a solution of 0.1

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								mL of phosphoric acid in 1000 mL of water. *Diluent 2*—Prepare a mixture of *Diluent 1* and acetonitrile (60:40). to: *Diluent 1*—Prepare a solution of 0.1 mL of phosphoric acid in 1000 mL of water.
GLYCERYL MONO AND DICAPRYLATE	IDENTIFICATION/*A. Fatty Acid Composition*	*USP43–NF38*	5794	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Standard solution 3*: Change USP Methyl Caproate RS, USP Methyl Caprylate RS, USP Methyl Caprate RS, USP Methyl Laurate RS, and USP Methyl Laurate RS.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: USP Methyl Caproate RS, USP Methyl Caprylate RS, USP Methyl Caprate RS, USP Methyl Laurate RS, and USP Methyl Myristate RS.
LEVONORDEFRIN	*Identification/B:*	*USP43–NF38*	2611	24-Apr-2020	1-May-2020	*NA*	*NA*	Change *Ultraviolet Absorption <197U>*— to: *Spectroscopic Identification Tests* <197>, *Ultraviolet-Visible Spectroscopy*: 197U
0.002 M EDETATE DISODIUM VS	REAGENTS AND REFERENCE TABLES/*Solutions*	*USP43–NF38*	6240	24-Apr-2020	1-May-2020	*NA*	*NA*	Change 0.0744 g to: 0.744 g
PANTOPRAZOLE SODIUM	ADDITIONAL REQUIREMENTS/*USP*	*USP43–NF38*	3388	24-Apr-2020	1-May-2020	*NA*	*NA*	In USP Pantoprazole Related

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Reference Standards <11>							Compound E RS: Change $C_{34}H_{28}F_4N_6O_8S_2$ 764.74 to: $C_{32}H_{28}F_4N_6O_8S_2$ 764.72
OXYBUTYNIN CHLORIDE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 2*	*Revision Bulletin (Official October 01, 2019)*	Online	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Buffer stage medium*: Change Simulated gastric fluid, to: Simulated intestinal fluid,
RALTEGRAVIR TABLETS	ASSAY/ *Procedure*	*USP43–NF38*	3834	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Analysis*: Change M_{r1} = molecular weight of raltegravir, 444.44 to: M_{r1} = molecular weight of raltegravir, 444.42
RALTEGRAVIR CHEWABLE TABLETS	IMPURITIES/*Organic Impurities*	*USP43–NF38*	3835	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Analysis*: Change M_{r1} = molecular weight of raltegravir,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								444.44 to: M_{r1} = molecular weight of raltegravir, 444.42
CETIRIZINE HYDROCHLORIDE ORALLY DISINTEGRATING TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP43–NF38*	915	24-Apr-2020	1-May-2020	*NA*	*NA*	In USP Cetirizine Related Compound A RS: Change 506.98 to: 506.97
OIL-SOLUBLE VITAMINS TABLETS	STRENGTH	*USP43–NF38*	5356	24-Apr-2020	1-May-2020	*NA*	*NA*	In *Vitamin E, Method 3*/*Analysis*: Change alpha -ocopheryl acetate to: alpha-tocopheryl acetate

Pagination

- First page « First
- Previous page ‹ Previous
- Page 1

- Page 2
- Page 3
- Page 4
- Page 5
- Page 6
- Page 7
- Page 8
- Page 9
- …
- Next page Next ›
- Last page Last »